{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:16:20Z","timestamp":1790226980922,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2017,10]]},"abstract":"Summary<\/jats:title>In this prospective study, we evaluated the effectiveness and tolerability of novel therapies against hepatitis C virus (HCV<\/jats:styled-content>) in a cohort of PWID<\/jats:styled-content> enrolled at our centre from April 2015 to July 2016. In this analysis, a total of 174 patients were included: eleven (6.3%) were treated with pegylated interferon (PEG<\/jats:styled-content>\u2010IFN<\/jats:styled-content>) and ribavirin (RBV<\/jats:styled-content>) containing regimens, 163 (93.7%) with IFN<\/jats:styled-content>\u2010free treatments. RBV<\/jats:styled-content> has been used in 70 patients (40.2%); 59 (33.9%) patients were in opioid substitution therapy (OST<\/jats:styled-content>) with methadone or buprenorphine. Overall, sustained virological response (SVR<\/jats:styled-content>) has been observed in 162 subject (93.1%), breakthrough (BT<\/jats:styled-content>) in three (1.7%), relapse in one (0.6%) and dropout in eight (4.6%). Treatment was interrupted for clinical conditions in seven patients: six (3.4%) had hepatic decompensation and one died for hepatocellular carcinoma (HCC<\/jats:styled-content>). In multivariate analysis, predictive factors of treatment failure were as follows: albumin level below 3\u00a0g\/dL<\/jats:styled-content> (OR<\/jats:styled-content>=7.190; 95% IC<\/jats:styled-content>=1.236\u201041.837; P<\/jats:italic><.001), MELD<\/jats:styled-content> score >10 (OR<\/jats:styled-content>=5.886; 95% IC<\/jats:styled-content>=1.411\u201035.994; P<\/jats:italic><.001) and years of HCV<\/jats:styled-content> infection >20 (OR<\/jats:styled-content>=1.286; 95% IC<\/jats:styled-content>=0.556\u20109.455; P=<\/jats:italic>.016). In conclusion, treatment with DAA<\/jats:styled-content>s was effective and well tolerated in PWID<\/jats:styled-content>; cirrhotic subjects with MELD<\/jats:styled-content>\u00a0>\u00a010 and albumin low level showed a higher risk of developing serious adverse events and treatment failure.<\/jats:p>","DOI":"10.1111\/jvh.12711","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T01:16:38Z","timestamp":1490577398000},"page":"850-857","source":"Crossref","is-referenced-by-count":30,"title":["Treatment with direct\u2010acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8326-4930","authenticated-orcid":false,"given":"L.","family":"Boglione","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases University of Turin Department of Medical Sciences Amedeo di Savoia Hospital Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mornese Pinna","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases University of Turin Department of Medical Sciences Amedeo di Savoia Hospital Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Nicol\u00f2","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases University of Turin Department of Medical Sciences Amedeo di Savoia Hospital Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cusato","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases University of Turin Department of Medical Sciences Amedeo di Savoia Hospital Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cariti","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases University of Turin Department of Medical Sciences Amedeo di Savoia Hospital Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Di Perri","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases University of Turin Department of Medical Sciences Amedeo di Savoia Hospital Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"D'Avolio","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases University of Turin Department of Medical Sciences Amedeo di Savoia Hospital Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61097-0"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-270"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26387"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01279.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e328338d9aa"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01080.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-28032010000300005"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_7_11_1","unstructured":"WHO.Section VIII: WHO toxicity grading scale for determining the severity of adverse events. WHO handbook for Reporting Results of Cancer Treatment.2003."},{"key":"e_1_2_7_12_1","unstructured":"AIFAIAoD. Registri Farmaci sottoposti a monitoraggio.2016."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2012.00468.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/600304"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1007"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit306"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01010.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit301"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12008"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12423"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13266"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12842"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12711","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T13:09:17Z","timestamp":1696165757000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/jvh.12711"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12711","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}